Epizyme gets $10 million from GSK under 2011 partnership

Epizyme Inc. (NASDAQ:EPZM) received a $10 million milestone payment from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) under a 2011 deal to discover and develop small molecule histone methyltransferase inhibitors for cancer and other diseases. The payment triggered upon GSK’s start of toxicology studies for one of three candidates it licensed from the biotech. ...